CASC19

Summary

CASC19 (cancer susceptibility 19, HGNC:49476) is a long non-coding RNA gene on chromosome 8q24.21.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:49476
Approved symbol	CASC19
Name	cancer susceptibility 19
Location	8q24.21
Locus type	RNA, long non-coding
Status	Approved
Aliases	CARLo-6
Ensembl gene	ENSG00000254166
Ensembl biotype	lncRNA
OMIM	617703
Entrez	103021165
RNAcentral	URS000075BCC9 — lncRNA, 324 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 119 — 107 lncRNA, 12 retained_intron

ENST00000500112, ENST00000521815, ENST00000523510, ENST00000641001, ENST00000641013, ENST00000641028, ENST00000641029, ENST00000641056, ENST00000641060, ENST00000641073, ENST00000641106, ENST00000641153, ENST00000641162, ENST00000641171, ENST00000641174, ENST00000641179, ENST00000641187, ENST00000641218, ENST00000641262, ENST00000641298, ENST00000641309, ENST00000641321, ENST00000641357, ENST00000641362, ENST00000641365, ENST00000641392, ENST00000641411, ENST00000641414, ENST00000641418, ENST00000641421, ENST00000641425, ENST00000641480, ENST00000641487, ENST00000641488, ENST00000641496, ENST00000641510, ENST00000641514, ENST00000641523, ENST00000641547, ENST00000641578, ENST00000641582, ENST00000641584, ENST00000641588, ENST00000641604, ENST00000641615, ENST00000641625, ENST00000641642, ENST00000641674, ENST00000641681, ENST00000641696, ENST00000641701, ENST00000641704, ENST00000641706, ENST00000641719, ENST00000641733, ENST00000641746, ENST00000641786, ENST00000641794, ENST00000641825, ENST00000641828, ENST00000641853, ENST00000641867, ENST00000641880, ENST00000641912, ENST00000641919, ENST00000641934, ENST00000641944, ENST00000641953, ENST00000641964, ENST00000641965, ENST00000641968, ENST00000641991, ENST00000642010, ENST00000642018, ENST00000642076, ENST00000642077, ENST00000642082, ENST00000642088, ENST00000642100, ENST00000642102, ENST00000642118, ENST00000642126, ENST00000642134, ENST00000642142, ENST00000657669, ENST00000663628, ENST00000664744, ENST00000701073, ENST00000701231, ENST00000730755, ENST00000730756, ENST00000730757, ENST00000730758, ENST00000730759, ENST00000730760, ENST00000730761, ENST00000730762, ENST00000730763, ENST00000730764, ENST00000730765, ENST00000730766, ENST00000730767, ENST00000730768, ENST00000730769, ENST00000730770, ENST00000730771, ENST00000730772, ENST00000730773, ENST00000730774, ENST00000730775, ENST00000730776, ENST00000730777, ENST00000730778, ENST00000730779, ENST00000730780, ENST00000730781, ENST00000730782, ENST00000730783, ENST00000730784

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000500112 — 2 exons

Exon	Start	End
ENSE00004059645	127204412	127209717
ENSE00004059659	127218810	127219271

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 91.59.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.9691 / max 273.7093, expressed in 106 samples.

FANTOM5 promoters (20 alternative TSS)

Promoter ID	TPM avg	Samples expressed
94846	4.1601	166
94847	0.7400	84
94855	0.3201	45
94856	0.2867	38
94853	0.1981	34
94848	0.1329	37
94851	0.1201	24
94857	0.0794	18
94841	0.0709	23
94852	0.0616	23

Top tissues by expression

133 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
lower esophagus mucosa	UBERON:0035834	91.59	gold quality
colonic epithelium	UBERON:0000397	81.46	gold quality
esophagus mucosa	UBERON:0002469	80.95	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.60	gold quality
tonsil	UBERON:0002372	77.86	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	77.44	gold quality
sural nerve	UBERON:0015488	76.19	gold quality
endometrium	UBERON:0001295	75.80	gold quality
liver	UBERON:0002107	75.69	gold quality
rectum	UBERON:0001052	73.23	gold quality
bone marrow cell	CL:0002092	73.13	gold quality
corpus callosum	UBERON:0002336	72.70	gold quality
adrenal tissue	UBERON:0018303	72.45	gold quality
calcaneal tendon	UBERON:0003701	71.07	gold quality
right lobe of liver	UBERON:0001114	70.39	gold quality
bone marrow	UBERON:0002371	69.51	gold quality
hindlimb stylopod muscle	UBERON:0004252	68.02	gold quality
esophagus	UBERON:0001043	66.91	gold quality
kidney	UBERON:0002113	66.06	gold quality
cortex of kidney	UBERON:0001225	65.35	gold quality
skeletal muscle tissue	UBERON:0001134	65.07	gold quality
metanephros cortex	UBERON:0010533	63.51	gold quality
right lobe of thyroid gland	UBERON:0001119	63.41	gold quality
monocyte	CL:0000576	63.40	gold quality
stomach	UBERON:0000945	63.24	gold quality
leukocyte	CL:0000738	63.03	gold quality
thyroid gland	UBERON:0002046	62.71	gold quality
blood	UBERON:0000178	62.48	gold quality
duodenum	UBERON:0002114	62.48	gold quality
left lobe of thyroid gland	UBERON:0001120	62.24	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	8.35

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 14)

• The majority (92 %) of risk-allele carriers at rs138042437 had a consistent estimated haplotype spanning approximately 100 kb of 8q24.21 that contained the minor alleles of three rare SNPs (dosage minor allele frequencies <1.7 %), rs183373024 (PRNCR1), previously associated SNP rs188140481, and rs138042437 (CASC19) (PMID:27262462)
• CASC19 expression was upregulated in colorectal cancer (CRC) tissues and CRC cell lines. Higher CASC19 expression was associated with poorer prognoses. CASC19 positively regulates CEMIP expression through targeting miR-140-5p. CASC19 may regulate the proliferation, epithelial-mesenchymal transition, and metastasizing ability of CRC cells by regulating microRNA-140-5p, as well as cell migration by inducing CEMIP. (PMID:31011255)
• LncRNA CASC19 promotes the proliferation, migration and invasion of non-small cell lung carcinoma via regulating miRNA-130b-3p. (PMID:31389608)
• Long non-coding RNA CASC19 is associated with the progression and prognosis of advanced gastric cancer. (PMID:31422382)
• CASC19 in HeLa cells negatively regulates the expression of miR-449b-5p, and down-regulating the expression of miR-449b-5p could partially reverse the effects of silencing CASC19 on HeLa cell proliferation, apoptosis and radiation sensitivity. (PMID:32074771)
• Long non-coding RNA CASC19 facilitates non-small cell lung cancer cell proliferation and metastasis by targeting the miR-301b-3p/LDLR axis. (PMID:32677267)
• LncRNA CASC19 contributed to the progression of pancreatic cancer through modulating miR-148b/E2F7 axis. (PMID:33155202)
• Long noncoding RNA CASC19 promotes glioma progression by modulating the miR4543p/RAB5A axis and is associated with unfavorable MRI features. (PMID:33416169)
• lncRNA CASC19 Contributes to Radioresistance of Nasopharyngeal Carcinoma by Promoting Autophagy via AMPK-mTOR Pathway. (PMID:33573349)
• LncRNA CASC19 promotes gastric cancer progression through preventing CREB1 protein ubiquitin/proteasome-dependent degradation. (PMID:36651836)
• LncRNA CASC19 Enhances the Radioresistance of Nasopharyngeal Carcinoma by Regulating the miR-340-3p/FKBP5 Axis. (PMID:36769373)
• Overexpression of CASC19 contributes to tumor progression and predicts poor prognosis after radical resection in hepatocellular carcinoma. (PMID:36805849)
• LncRNA CASC19: a novel oncogene involved in human cancer. (PMID:37029242)
• CASC19: An Oncogenic Long Non-coding RNA in Different Cancers. (PMID:38544395)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.